Baxter SAS and Physidia sign a co-promotion agreement to support homecare for dialysis patients in France

As part of a co-promotion agreement, Baxter SAS and the Physidia company wish to promote homecare for patients with kidney failure undergoing dialysis.

The objective of this agreement is to offer patients leaving peritoneal dialysis the opportunity to receive frequent hemodialysis treatment at home using Physidia’s S³ system. In addition, patients will benefit from Baxter’s HDx therapy with the Theranova® dialyzer, which is compatible with the S³ system.

“Baxter is committed to providing healthcare professionals with comprehensive and innovative care solutions. Especially at home, through connected peritoneal dialysis and the possibility of offering, in co-promotion with Physidia, a continuum of treatment by daily hemodialysis that can benefit from HDx therapy, currently used in centers.” said Marie-Claire Taine, Vice-President Renal Care Western Europe.

“Physidia, a leader in the frequent home hemodialysis sector in France and in strong growth in Europe, has been working for 10 years to develop this form of frequent home hemodialysis. We are delighted to be able to offer our technology and services to patients leaving peritoneal dialysis in France,” added Didier Candelot, President of Physidia.

Guillaume Lefèvre, Renal Care Business Unit Director – Baxter SAS in France and Steve Haupt, Vice President Sales & Marketing at Physidia said, “We are delighted with this collaboration which demonstrates a shared vision of care that promotes patient autonomy, quality of life and quality of dialysis.“